» Articles » PMID: 38774399

Factors Influencing Survival and Mortality Among Adult Aboriginal Australians with Bronchiectasis-A 10-year Retrospective Study

Overview
Specialty General Medicine
Date 2024 May 22
PMID 38774399
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The prevalence of bronchiectasis among adult Aboriginal Australians is higher than that of non-Aboriginal Australians. However, despite evidence to suggest higher prevalence of bronchiectasis among Aboriginal people in Australia, there is sparce evidence in the literature assessing clinical parameters that may predict survival or mortality in this population.

Methods: Aboriginal Australians residing in the Top End Health Service region of the Northern Territory of Australia aged >18 years with chest computed tomography (CT) confirmed bronchiectasis between 2011 and 2020 were included. Demographics, body mass index (BMI), medical co-morbidities, lung function data, sputum microbiology, chest CT scan results, hospital admissions restricted to respiratory conditions and all-cause mortality were assessed.

Results: A total of 459 patients were included, of whom 146 were recorded deceased (median age at death 59 years). Among the deceased cohort, patients were older (median age 52 vs. 45 years, = 0.023), had a higher prevalence of chronic obstructive pulmonary disease (91 vs. 79%, = 0.126), lower lung function parameters (median percentage predicted forced expiratory volume in 1 s 29 vs. 40%, = 0.149), a significantly greater proportion cultured non- fungi (65 vs. 46%, = 0.007) and (46 vs. 28%, = 0.007) on sputum microbiology and demonstrated bilateral involvement on radiology. In multivariate models advancing age, prior culture and Intensive care unit (ICU) visits were associated with increased odds of mortality. Higher BMI, better lung function on spirometry, prior positive sputum microbiology for and use of inhaled long-acting beta antagonist/muscarinic agents may have a favourable effect.

Conclusion: The results of this study may be of use to stratify high risk adult Aboriginal patients with bronchiectasis and to develop strategies to prevent future mortality.

Citing Articles

Retrospective cross-sectional study on bronchiectasis in adult Aboriginal Australians: disease characteristics and comparison with ethnically diverse global bronchiectasis registry cohorts.

Heraganahally S, Gibbs C, J Ravichandran S, Erdenebayar D, Chen W, Abeyaratne A BMJ Open Respir Res. 2025; 12(1).

PMID: 39842857 PMC: 11784196. DOI: 10.1136/bmjresp-2023-002139.


Applicability and Validity of the "Bronchiectasis Severity Index" (BSI) and "FACED" Score in Adult Aboriginal Australians.

Howarth T, Gibbs C, Abeyaratne A, Heraganahally S Int J Chron Obstruct Pulmon Dis. 2024; 19:2611-2628.

PMID: 39650744 PMC: 11625430. DOI: 10.2147/COPD.S482848.


Case Report: Effects of Environmental Smoke Exposure on Respiratory Conditions-A Report of an Aboriginal Man Fire Hunting for Mud Turtles in the Top End, Northern Territory of Australia.

Nockles V, Hill E, Howarth T, Browning S, Wurrawilya S, Ford P Am J Trop Med Hyg. 2024; 111(6):1373-1377.

PMID: 39406209 PMC: 11619486. DOI: 10.4269/ajtmh.24-0366.

References
1.
McDonnell M, Aliberti S, Goeminne P, Restrepo M, Finch S, Pesci A . Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med. 2016; 4(12):969-979. PMC: 5369638. DOI: 10.1016/S2213-2600(16)30320-4. View

2.
Lee S, Lee J, Lee S, Oh Y . Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study. J Thorac Dis. 2021; 13(1):169-177. PMC: 7867804. DOI: 10.21037/jtd-20-1282. View

3.
Goeminne P, Nawrot T, Ruttens D, Seys S, Dupont L . Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med. 2014; 108(2):287-96. DOI: 10.1016/j.rmed.2013.12.015. View

4.
Sin S, Yun S, Kim J, Park C, Cho J, Choi S . Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis. Respir Res. 2019; 20(1):271. PMC: 6889428. DOI: 10.1186/s12931-019-1243-3. View

5.
Seyedshahabedin M, Howarth T, Mo L, Biancardi E, Heraganahally S . Flexible bronchoscopy indications and outcomes between indigenous and non-indigenous patients in the Northern Territory of Australia. Intern Med J. 2022; 53(9):1634-1641. DOI: 10.1111/imj.15865. View